Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.15%
As of Thursday, October 08, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.15%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Commentary & Analysis
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 8.51%
As of Wednesday, October 07, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 8.51%, which has investors questioning if this is right time to buy.Michael Rose
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 7.26%
As of Tuesday, October 06, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 7.26%, which has investors questioning if this is right time to buy.Michael Rose
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 6.95%
As of Monday, October 05, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 6.95%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 5.32%
As of Thursday, October 01, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $563.8 | $519.2 | 39% |
|
| Shares Out (Mil) | 142.7 | 42.8 | 70% |
|
| Institutional Ownership | 96.1% | 82.8% | 69% |
|
| Float (Mil) | 101.2 | 44.4 | 61% |
|
| Beta | 0.80 | 0.71 | 48% |
|
| Avg Daily Volume (000s) | 5,147 | 394 | 92% |
|
| Price Change (52-week) |
101.6% | 60.2% | 94% |
|
| Growth | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.7% | 6.1% | 30% |
|
| Net Income (5yr) | (4.9%) | (2.0%) | 34% |
|
| EPS (5yr) | 15.1% | 15.0% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 34.4% | (15.1%) | 89% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 11 | |
| Current EPS | ($0.165) | ($0.644) | ($0.787) | |
| Month Ago EPS | ($0.165) | ($0.644) | ($0.787) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.173) | ($0.655) | ($0.829) | |
| Year/Year Chg | 9.3% | 21.5% | 48.3% | |
| Financials | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $416 | 8% |
|
| Net Income (TTM) (Mil) | ($76) | ($11) | 13% |
|
| EPS (TTM) | ($0.586) | ($0.700) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $6 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 18% |
|
| Enterprise Value (Q1) (Mil) | $641 | $494 | 36% |
|
| Valuation | ACRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.30 | 2.31 | 76% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (757.7%) | 69.4% | 0% |
|
| Net Margin | (921.5%) | 3.2% | 0% |
|
| ROA | (41.1%) | (22.2%) | 13% |
|
| ROE | (59.1%) | (21.4%) | 14% |
|
| Liabilities to Assets | 30.7% | 32.8% | 22% |
|
| F-Score | 3 | 3 | 18% |
|
Aclaris Therapeutics, Inc. did not pass any screens on 10/9/2026.
